The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding.
Concentrations of the potent, HIV(human immunodeficiency virus) inactivating protein, cyanovirin-N (CV-N), which completely inhibit HIV-1 infectivity, do not block the binding of soluble CD4-receptor (sCD4) to HIV-1 lysates nor the attachment of intact HIV-1 virions to several target T-cell lines. Furthermore, in contrast to the known disassociative effects of sCD4 on viral envelope glycoproteins, treatment of HIVRF with high concentrations of CV-N results in complete viral inactivation but without apparent shedding of gp120 or other ultrastructural changes. These results are consistent with the view that the virucidal effects of CV-N result from interference with step(s) in the fusion process subsequent to the initial binding of the virus to target cells.
Mariner
J M
JM
Laboratory of Drug Discovery Research and Development, National Cancer Institute, Frederick Cancer Research & Development Center, Maryland 21702-1201, USA.
McMahon
J B
JB
O'Keefe
B R
BR
Nagashima
K
K
Boyd
M R
MR
D019380:Anti-HIV Agents / Q000494:pharmacology*; D001426:Bacterial Proteins; D015704:CD4 Antigens / Q000187:drug effects / Q000502:physiology*; D002352:Carrier Proteins / Q000494:pharmacology*; D002460:Cell Line; D004797:Enzyme-Linked Immunosorbent Assay; D015699:HIV Envelope Protein gp120 / Q000187:drug effects / Q000502:physiology*; D015497:HIV-1 / Q000187:drug effects* / Q000502:physiology / Q000648:ultrastructure; D006801:Humans; D007700:Kinetics
D019380:Anti-HIV Agents; D001426:Bacterial Proteins; D015704:CD4 Antigens; D002352:Carrier Proteins; D015699:HIV Envelope Protein gp120; C107733:cyanovirin N